Author Loeffler, Markus

1 to 20 of 122 Items
  • 2000 | Conference Abstract
    ​ ​Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: Updated results of the German Hodgkin's Lymphoma Study Group.​
    Diehl, V.; Franklin, J.; Sieber, M.; Hasenclever, D.; Wolf, J.; Engert, A. & Hermann, R. et al.​ (2000)
    Blood, 96(11) pp. 576A​-+. 
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2002 | Conference Abstract
    ​ ​Significant dose escalation of the CHOEP regimen in young patients with aggressive non Hodgkin's lymphoma is feasible: Results of a prospective randomized phase I/II trial.​
    Truemper, L. H.; Kloss, M.; Held, G.; Schmits, R.; Franke, A.; Berdel, W. E. & Fischer, T. et al.​ (2002)
    Blood, 100(11) ​44th Annual Meeting of the American-Society-of-Hematology​, PHILADELPHIA, PENNSYLVANIA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2002 | Conference Abstract
    ​ ​Mega-CHOEP repeated high dose therapy as treatment of aggressive NHL: Critical impact of time scheduling.​
    Glass, B.; Kloess, M.; Engert, A.; Berdel, W. E.; Metzner, B.; Truemper, L. H. & Loeffler, M. et al.​ (2002)
    Blood, 100(11) ​44th Annual Meeting of the American-Society-of-Hematology​, PHILADELPHIA, PENNSYLVANIA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2003 | Conference Abstract
    ​ ​Repeated high-dose therapy with rituximab followed by autologous stem cell transplantation (ASCT) as primary treatment of high-risk aggressive NHL.​
    Glass, B.; Kloess, M.; Engert, A.; Berdel, W. E.; Metzner, B.; Truemper, L. H. & Loeffler, M. et al.​ (2003)
    Blood, 102(11) ​45th Annual Meeting of the American-Society-of-Hematology​, SAN DIEGO, CALIFORNIA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2003 | Journal Article
    ​ ​Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)​
    Wunderlich, A.; Kloess, M.; Reiser, M.; Rudolph, C.; Truemper, L. H.; Bittner, S. & Schmalenberg, H. et al.​ (2003) 
    Annals of Oncology, 14(6) pp. 881​-893​.​ DOI: https://doi.org/10.1093/annonc/mdg249 
    ​Details  DOI  PMID  PMC  WoS 
  • 2004 | Conference Abstract
    ​ ​Early dose intensity is critical in patients with aggressive lymphoma: A randomized study comparing identical doses of cyclophosphamide, adriamycin, vincristine, etoposide, and prednisolone given as 4 or 6 cycles followed by repetitive transplantation of stem cells (Mega-CHOEP).​
    Glass, B.; Kloess, M.; Reiser, M.; Berdel, W. E.; Ho, A. D.; Truemper, L. H. & Loeffler, M. et al.​ (2004)
    Blood, 104(11) ​46th Annual Meeting of the American-Society-of-Hematology​, San Diego, CA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2004 | Conference Abstract
    ​ ​First analysis of the completed Mabthera International (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease.​
    Pfreundschuh, M.; Truemper, L. H.; Gill, D. S.; Osterborg, A.; Pettengell, R.; Trneny, M. & Imrie, K. et al.​ (2004)
    Blood, 104(11) ​46th Annual Meeting of the American-Society-of-Hematology​, San Diego, CA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2004 | Conference Abstract
    ​ ​Repetitive high-dose therapy with dose escalated CHOP plus Etoposide followed by autologous stem cell transplantation (Mega-CHOEP) in younger patients with primary diagnosis of aggressive NHL and elevated LDH at diagnosis: Final analysis​
    Schmitz, N.; Kloess, M.; Engert, A.; Berdel, W. E.; Metzner, B.; Truemper, L. H. & Loeffler, M. et al.​ (2004)
    Blood, 104(11) ​46th Annual Meeting of the American-Society-of-Hematology​, San Diego, CA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2004 | Conference Abstract
    ​ ​Nad(p)h oxidase and MRP genetic polymorphisms associate with doxorubicin-induced cardiotoxicity​
    Wojnowski, L.; Schlueter, G.; Vonhof, S.; Kulle, B.; Bickeboeller, H. ; Loeffler, M. & Pfreundschuh, M. et al.​ (2004)
    Journal of Clinical Oncology, 22(14) ​40th Annual Meeting of the American-Society-of-Clinical-Oncology​, New Orleans, LA.
    Alexandria​: Amer Soc Clinical Oncology.
    ​Details  PMID  PMC  WoS 
  • 2004 | Conference Abstract
    ​ ​Association of NAD(P)H oxidase and MRP genetic polymorphisms with doxorubicin-induced cardiotoxicity​
    Wojnowski, L.; Schluter, G.; Vonhof, S.; Kulle, B.; Bickeboeller, H. ; Toliat, M. R. & Suk, E. K. et al.​ (2004)
    Naunyn-Schmiedeberg s Archives of Pharmacology, 369 ​45th Spring Meeting of the German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology​, Mainz, GERMANY.
    New york​: Springer.
    ​Details  WoS 
  • 2004 | Conference Abstract
    ​ ​NAD(P)H oxidase and MRP genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity​
    Schirmer, M. A.; Wojnowski, L.; Schluter, G.; Vonhof, S.; Kulle, B.; Bickeboeller, H.   & Toliat, M. R. et al.​ (2004)
    Circulation, 110(17) pp. 807​-808. ​77th Scientific Meeting of the American-Heart-Association​, New Orleans, LA.
    Philadelphia​: Lippincott Williams & Wilkins.
    ​Details  WoS 
  • 2004 | Journal Article
    ​ ​Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL​
    Pfreundschuh, M.; Truemper, L. H.; Kloess, M.; Schmits, R.; Feller, A. C.; Rube, C. & Rudolph, C. et al.​ (2004) 
    Blood, 104(3) pp. 634​-641​.​ DOI: https://doi.org/10.1182/blood-2003-06-2095 
    ​Details  DOI  PMID  PMC  WoS 
  • 2004 | Journal Article
    ​ ​Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL​
    Pfreundschuh, M.; Truemper, L. H.; Kloess, M.; Schmits, R.; Feller, A. C.; Rudolph, C. & Reiser, M. et al.​ (2004) 
    Blood, 104(3) pp. 626​-633​.​ DOI: https://doi.org/10.1182/blood-2003-06-2094 
    ​Details  DOI  PMID  PMC  WoS 
  • 2005 | Conference Abstract
    ​ ​Dose escalated CHOP plus etoposide followed by repetitive autologous stem cell transplantation (MegaCHOEP) with or without rituximab for primary treatment of aggressive NHL.​
    Glass, B.; Kloess, M.; Reiser, M.; Metzner, B.; Truemper, L. H.; Loeffler, M. & Pfreundschuh, M. et al.​ (2005)
    Blood, 106(11) ​47th Annual Meeting of the American-Society-of-Hematology​, Atlanta, GA.
    Washington​: Amer Soc Hematology.
    ​Details  WoS 
  • 2005 | Conference Abstract
    ​ ​Dose escalated CHOP plus etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL.​
    Glass, B.; Kloess, M.; Engert, A.; Berdel, W. E.; Metzner, B.; Tromper, L. & Loeffler, M. et al.​ (2005)
    Journal of Clinical Oncology, 23(16) ​41st Annual Meeting of the American-Society-of-Clinical-Oncology​, Orlando, FL.
    Alexandria​: Amer Soc Clinical Oncology.
    ​Details  WoS 
  • 2005 | Conference Abstract
    ​ ​Interleukin-10 gene promoter polymorphisms in aggressive non-Hodgkin lymphoma​
    Kube, D.; Hua, T.; Kulle, B.; Gocht, D.; Kloess, M.; Brockmoeller, J. & Wojnowski, L. et al.​ (2005)
    Annals of Oncology, 16 ​9th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
    Oxford​: Oxford Univ Press.
    ​Details  WoS 
  • 2005 | Conference Abstract
    ​ ​Toxicity risk groups in aggressive NHL - Prognostic factors for hematotoxicity​
    Kloess, M.; Schmits, R.; Truemper, L. H.; Pfreundschuh, M. & Loeffler, M.​ (2005)
    Annals of Oncology, 16 ​9th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
    Oxford​: Oxford Univ Press.
    ​Details  WoS 
  • 2005 | Conference Abstract
    ​ ​Prognostic relevance of extrlymphatic involvement in aggressive lymphoma Results from a large randomized multicenter trial of the DSHNHL​
    Kempf, B.; Kloess, M.; Schmits, R.; Loeffler, M.; Truemper, L. H. & Pfreundschuh, M.​ (2005)
    Annals of Oncology, 16 ​9th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
    Oxford​: Oxford Univ Press.
    ​Details  WoS 
  • 2005 | Journal Article | Research Paper
    ​ ​NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity​
    Wojnowski, L.; Kulle, B.; Schirmer, M. ; Schlüter, G.; Schmidt, A.; Rosenberger, A.   & Vonhof, S. et al.​ (2005) 
    Circulation, 112(24) pp. 3754​-3762​.​ DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.576850 
    ​Details  DOI  PMID  PMC  WoS 
  • 2006 | Conference Abstract
    ​ ​Dose escalated CHOP plus etoposide with repetitive autologous stem cell transplantation as primary treatment for aggressive T-NHL: results of three consecutive phase I/II trials​
    Nickelsen, M.; Kloess, M.; Loeffler, M.; Glass, B.; Truemper, L. H.; Pfreundschuh, M. & Schmitz, N.​ (2006)
    Bone Marrow Transplantation, 37 , Hamburg, GERMANY.
    London​: Nature Publishing Group.
    ​Details  WoS 

Researcher

Göttingen All

Sort

issue date

ASC DESC

Items per Page

10 20 50 100